Skip to main content
PMC home page
HHS Author Manuscripts logoLink to HHS Author Manuscripts
. Author manuscript; available in PMC: 2019 Jul 3.
Published in final edited form as: Vaccine. 2018 Nov 22;37(1):25–33. doi: 10.1016/j.vaccine.2018.11.048

Prioritization of risk groups for influenza vaccination in resource limited settings – A case study from South Africa

Meredith L McMorrow a,b,c,*, Stefano Tempia a,b,d,*, Sibongile Walaza d,e, Florette K Treurnicht d, Wayne Ramkrishna f, Eduardo Azziz-Baumgartner a,c, Shabir A Madhi g,h, Cheryl Cohen d,e
PMCID: PMC6470296  NIHMSID: NIHMS1012564  PMID: 30471956

Abstract

Background:

Due to competing health priorities, low- and middle-income countries (LMIC) may need to prioritize between different influenza vaccine risk groups. Risk group prioritization may differ in LMIC based upon programmatic feasibility, country-specific prevalence of risk conditions and influenza-associated morbidity and mortality.

Methods:

In South Africa, we collected local disease burden data (both published and unpublished) and published vaccine efficacy data in risk groups and healthy adults. We used these data to aid policy makers with risk group prioritization for influenza vaccination. We used the following formula to assess potential vaccine averted disease in each risk group: rate of influenza-associated hospitalization (or death) per 100,000 population * influenza vaccine efficacy (VE). We further estimated the cost per hospital day averted and the cost per year of life saved by influenza vaccination.

Results:

Pregnant women, HIV-infected adults, and adults and children with tuberculosis disease had among the highest estimates of hospitalizations averted per 100,000 vaccinated and adults aged 65 years and older had the highest estimated deaths averted per 100,000 vaccinated. However, when assessing both the cost per hospital day averted (range: USD148–1,344) and the cost per year of life saved (range: USD112–1,230); adults and children with TB disease, HIV-infected adults and pregnant women had the lowest cost per outcome averted.

Discussion:

An assessment of the potential disease outcomes averted and associated costs may aid policymakers in risk group prioritization for influenza vaccination.

Keywords: Influenza, Vaccine policy, Hospitalization, Mortality, South Africa

1. Introduction

In 2012, the World Health Organization (WHO) published a revised position paper on the use of influenza vaccines [1]. Collection of country-specific data on risk groups, influenza disease burden and vaccine cost-effectiveness was encouraged to aid in policy development, especially in low- and middle-income countries (LMIC). Risk groups to be considered for vaccination included pregnant women, children aged 6–59 months, adults aged 65 years and older, individuals with specific chronic medical conditions, and healthcare workers. Given available data, WHO’s Strategic Advisory Group of Experts on Immunization recommended the prioritization of pregnant women for seasonal influenza vaccination to protect both pregnant women and young infants against laboratory-confirmed influenza. As there were limited data available about influenza in pregnancy in LMIC, this recommendation was largely based on programmatic feasibility [2], the findings of a single randomized controlled trial from Bangladesh [3,4], and observational data on vaccine safety and effectiveness from high-income countries [5–7]. Influenza surveillance capacity in LMIC has expanded since the 2009 influenza A(H1N1) pandemic [8–10]. There is a growing body of literature about the burden of and risk groups for influenza-associated severe disease and death in LMIC [11–14]. In South Africa, as in high-income countries, young children and adults aged ≥65 years share a disproportionate burden of influenza-associated hospitalizations and deaths [15,16]; however, HIV-infection and tuberculosis (TB) disease are also important risk factors for severe outcomes in this context [17–20]. Thus, risk group prioritization may differ in LMIC based upon country-specific prevalence of risk conditions and influenza-associated morbidity and mortality.

Due to competing health priorities, LMIC may have limited resources to dedicate to the purchase of influenza vaccines. In such cases, vaccine needs of high risk groups may exceed the available resources for vaccine procurement. Prioritization among high risk groups may therefore be necessary to optimize influenza vaccine distribution in order to achieve the greatest impact on severe disease outcomes. In addition to assessing the burden of severe disease among different risk groups, the efficacy and effectiveness of influenza vaccines in the high risk group may also be relevant to risk group prioritization. There is evidence of reduced vaccine efficacy in children aged 6–23 months [21,22], adults aged 65 years and older [23] and individuals with specific chronic medical conditions (e.g. renal disease)[24]; however, influenza vaccine efficacy in pregnant women appears comparable to that of healthy adults and also prevents influenza in the young infant [15,25]. There are no data on the efficacy of influenza vaccines in persons with TB disease. Furthermore, risk groups with existing platforms for immunization service delivery (e.g. infants through the Expanded Programme on Immunisation (EPI) and pregnant women through antenatal care (ANC)) may be easier to access than groups that do not present for frequent, scheduled visits (e.g. the elderly). HIV-infected adults and persons with TB disease not receiving care are potentially at even higher risk of influenza-associated hospitalization or death than those in care [26,27] due to immunosuppression, but there is no existing mechanism to provide influenza vaccine to these high risk individuals. HIV and TB clinics may also be platforms for immunization service delivery; however, immunization services may not currently exist in these clinics. Likewise, persons aged 65 years and older are less likely to seek care [28]. There are limited existing data on influenza vaccine cost-effectiveness in LMIC [29]. Due to the lower cost of hospitalization and outpatient consultation, influenza vaccines may not be as cost effective in LMIC as in high-income countries. Likewise, high rates of unemployment may reduce influenza-associated productivity losses.

Given the complexities associated with influenza vaccine prioritization, we sought to aid policy makers to make evidence-based decisions on risk group prioritization in South Africa.

2. Methods

Using locally available disease burden data (both published and unpublished) and published literature on vaccine efficacy in high risk groups and healthy adults, we developed an evidence-based approach to aid policy makers in South Africa with risk group prioritization for influenza vaccination. For each risk group (pregnant women, HIV-infected adults, children aged 6–23 months1, adults aged 65 years and older, healthcare workers, adults and children with tuberculosis disease (all ages), and adults and children aged 5–64 years with non-HIV chronic illness) we sought to identify data on risk of hospitalization or death from influenza infection, population size, influenza vaccine efficacy (VE) and existing platform(s) for service delivery. VE estimates from randomized controlled trials were preferred over observational VE estimates. When no data were available (e.g. current influenza vaccine coverage) we used national estimates of influenza vaccine coverage from prior campaigns, or estimates of vaccine coverage from other vaccines targeting similar risk groups (e.g. tetanus vaccine coverage for pregnant women). We did not attempt to assess the potential impact of vaccination on disease transmission or to weigh the potential benefit of maternal influenza immunization on birth outcomes [30]. The data sources used in this study are provided in Table 1.

Table 1.

Sources of data on priority risk groups for influenza vaccination in South Africa, 2016.

Data Source Estimation method
Population Estimates
Population estimate for pregnant women Statistics South Africa Mid-Year Population Estimates, 2016 [31] Assumed equal to annual live births
Population estimate for HIV-infected adults aged 15–64 years Statistics South Africa Mid-Year Population Estimates, 2016 [31]; Thembisa Model [32] Applied 2016 HIV prevalence by year of age from the Thembisa model to mid-year population estimates for individuals aged15–64 years
Population estimate for children aged 6–23 months Statistics South Africa Mid-Year Population Estimates, 2016 [31] Sum of half of infants aged 0–11 months plus all children aged 12–23 months
Population estimate for adults aged ≥ 65 years Statistics South Africa Mid-Year Population Estimates, 2016 [31] Sum of adults aged ≥ 65 years
Population estimate for healthcare workers Health Professions Council of South Africa (HPCSA) [53]; South African Nursing Council (SANC) [54]; Shisana et al. [55] Sum of registered providers from HPCSA (3 May 2016) and nurses from SANC (2015); HIV prevalence in healthcare workers
Population estimate for adults and children with TB disease WHO World TB Report 2015, South Africa country profile [56] Assumed no change from 2014 estimate
Population estimate for adults and children aged 5–64 years with other chronic disease South Africa National Health and Nutrition Survey (SA NHANES) [33]; Schouten et al. [34] Determined age-standardized prevalence of 1 or more of the following underlying conditions: Adults aged 15–64 years – cardiovascular disease, diabetes, history of tuberculosis, more than 10 pack-years smoking, or BMI ≥ 35; Children aged 0–14 years – BMI < 97%ile, history of >3% weight for age, or seizure disorder. Adjusted for increased prevalence of comorbid conditions in HIV-infected compared to HIV-uninfected, odds ratio 1.58 (95% CI 1.23–2.03).
Hospitalization Rates
Influenza-associated hospitalization rate in pregnant women Tempia et al. [35]; Van Kerkhoven et al. [11] Age and HIV-standardized rates were used to estimate influenza-associated hospitalization rates for adults aged 15–49 years and adjusted for the increased risk of influenza-associated hospitalization among pregnant women: relative risk 6.8 (95% CI 4.5–12.3).
Influenza-associated hospitalization rate in infants aged 0–5 months McMorrow et al. [36] Rate from local data for children aged 0–5 months, 2011–2016
Influenza-associated hospitalization rate in HIV-infected adults aged 15–64 years Tempia et al. [35] Rate from local data for HIV-infected adults aged 15–64 years, 2013– 2015
Influenza-associated hospitalization rate in children aged 6–23 months McMorrow et al. [36] Unpublished rate from local data for children aged 6–23 months, 2011–2016
Influenza-associated hospitalization rate in adults aged ≥ 65 years Tempia et al. [35] Rate from local data for adults aged ≥ 65 years, 2013–2015
Influenza-associated hospitalization rate in healthcare workers Tempia et al. [35]; SANC [54]; Shisana et al. [55] Unpublished rate from local data, 2013–2015 adjusted for age distribution and HIV-prevalence of healthcare workers
Influenza-associated hospitalization rate in adults and children with TB disease Lawn et al. [57]; WHO World TB Report 2015, South Africa country profile [56]; Tempia et al. [35]; Abadom et al. [37] Age-adjusted TB incidence was estimated from the literature. HIV prevalence was assumed to be 60% among TB-infected adults and children. Age and HIV-standardized rates were adjusted for the increased odds of influenza-associated hospitalization from recently published local data: case-population ratio 1.85 (95% CI 1.68–2.02).
Influenza-associated hospitalization rate in adults and children aged 5–64 years with other chronic disease Tempia et al. [35]; Abadom et al. [37] Age and HIV-standardized rates were adjusted for the increased odds of influenza-associated hospitalization in those with chronic illness (assumed from hospitalization in last year) compared to HIV-uninfected adults from local data: case-population ratio 2.07 (95% CI 1.92–2.23).
Death rates
Influenza-associated death rate in pregnant women Tempia et al. [39] Published rate from local data, 1999–2009
Influenza-associated death rate in infants aged 0–5 months Cohen et al. [40] Unpublished rate from local data for infants aged 0–11 months, 2009–2013
Influenza-associated death rate in HIV-infected adults aged 15–64 years Tempia et al. [16] Published rate from local data, 1998–2009
Influenza-associated death rate in children aged 6–23 months Cohen et al. [40] Unpublished rate from local data for children aged 0–11 months and 1–4 years, 2009–2013
Influenza-associated death rate in adults aged ≥ 65 years Cohen et al. [40] Unpublished rate from local data, 2009–2013
Influenza-associated death rate in healthcare workers Cohen et al. [40] Unpublished rate from local data for adults aged 20–64 years, 2009–2013
Influenza-associated death rate in adults and children with TB disease Walaza et al. [19] Published rate from local data, 1999–2009
Influenza-associated death rate in adults and children aged 5–64 years with other chronic disease Cohen et al. [40]; Mertz et al. [38] Unpublished rate from local data for children and adults aged 5–64 years, 2009–2013 adjusted for increased odds of death among persons with chronic illness: odds ratio 2.04 (95% CI 1.74–2.39).
Vaccine efficacy
Vaccine efficacy estimate for pregnant women Madhi et al. [15] Tapia et al. [25] Estimated using 1-risk ratio (RR). RR estimated using random effects Mantel-Haenszel model of published randomized controlled trials of inactivated influenza vaccine in pregnant women.
Maternal influenza vaccine efficacy against influenza-associated illness in infants aged 0–5 months Madhi et al. [15] Tapia et al. [25] Zaman et al. [3] Estimated using 1-risk ratio (RR). RR estimated using random effects Mantel-Haenszel model of published randomized controlled trials of inactivated influenza vaccine in pregnant women.
Vaccine efficacy estimate for HIV-infected adults Madhi et al. [58] Assumed no change.
Vaccine efficacy estimate for children aged 6–23 months Hoberman et al. [42]Vesikari et al. [22] Estimated using 1-RR. RR estimated using random effects Mantel-Haenszel model of published randomized controlled trials of inactivated influenza vaccine in children aged 6–23 months.
Vaccine efficacy estimate for adults aged ≥ 65 years Darvishian et al. [23] Meta-analysis of 35 test-negative design case-control studies
Vaccine efficacy estimate for healthcare workers Demicheli et al. [41] Assumed equivalent to healthy adults in Cochrane Review and meta-analysis of 20 RCTs
Vaccine efficacy estimate for adults and children with TB Darvishian et al. [23] No published studies of VE in persons with TB; we used the VE estimate from adults aged 65 years and older.
Vaccine efficacy estimate for adults and children aged 5–64 years with chronic illnesses Darvishian et al. [23] Due to the limited data on vaccine efficacy among persons with chronic illnesses (Michiels et al. [59]) we used the VE estimate from adults aged 65 years and older.
Vaccine coverage
Current influenza vaccine coverage estimates for all risk groups Ramkrishna [43] Assumed no change from 2015. HIV and TB-infected adults included in chronic disease estimates per author.
Current influenza vaccine coverage estimates for healthcare workers Haviari et al. [44] No estimate available for South Africa. Most low and middle income countries had vaccine low influenza vaccine coverage in this review so we chose 10% as an estimate of current influenza vaccine coverage in South African healthcare workers.
Current vaccine coverage estimates for measles second dose (children) and tetanus toxoid (pregnant women) WHO/UNICEF South Africa estimates [45] Assumed no change from 2015 estimate
Other parameters
Proportion of HIV-infected currently in care and treatment Thembisa model 2.5 [32] Used model assumptions for 2016
Proportion of persons with TB disease currently receiving treatment WHO World TB Report 2015, South Africa country profile [56] Assumed no change from 2014 estimate
Cost of a single dose of inactivated influenza vaccine Pan American Health Organization Revolving Fund Vaccine Prices for 2016 [46] USD3 (range USD2.80–3.95)
Mean duration of influenza-associated hospitalization in days for each risk group NICD unpublished data Severe respiratory illness surveillance 2009–2016
Expectation of life in years by age WHO Global Health Observatory [47]; Johnson et al. [48] Assumed no change from 2013 estimates
Open in a new tab

2.1. Population estimates

Population estimates for all risk groups were publicly available except for persons with chronic illnesses (excluding HIV) and pregnant women [31,32]. For pregnant women we used the total live births from mid-year 2016 population estimates [31]. To estimate the number of HIV-uninfected children and adults aged 5–64 years with chronic illness we obtained data on self-reported chronic illness from the South Africa National Health and Nutrition Survey (SA NHANES) [33]. The SA NHANES survey did not collect data on HIV status. To adjust for the increased prevalence of chronic conditions among HIV-infected children and adults we used the following formula [34]: the prevalence of underlying conditions in HIV-uninfected children and adults by age group = SA NHANES survey age group-specific prevalence of underlying conditions/[1 + 0.58 (age group-specific HIV-prevalence)]. We applied this prevalence estimate by age group (5–14y, 15–24y, 25–44y, and 45–64y) to the total HIV-uninfected population in the age stratum to estimate the population who would potentially seek care in non-HIV chronic illness clinics.

2.2. Rates of influenza-associated hospitalization

Rates of influenza-associated hospitalization were calculated using hospital-based surveillance at sentinel sites adjusting for non-enrolment, health-seeking behavior, and the attributable fraction of influenza-associated disease, stratified by age and HIV status [35,36]; see also Supplemental information). Rates were adjusted for specific risk factors (e.g. pregnancy, chronic illness) based upon the increased odds of influenza-associated hospitalization derived from hospital-based surveillance and data on the age-adjusted prevalence of the risk factor in the general population, or from the literature [11,37,38].

2.3. Rates of influenza-associated death

Influenza-associated deaths were estimated from published ecological models of seasonal excess mortality from vital statistics data using laboratory-confirmed influenza as a covariate [16,19,39,40]. Monte Carlo simulations using 5000 iterations based on a Poisson distribution in SAS 9.3 (SAS Institute, Cary, NC) were used to develop means and 95% confidence intervals for estimates of hospitalization or mortality rates requiring adjustment for risk factors.

2.4. Vaccine efficacy estimates

Vaccine efficacy (VE) of inactivated influenza vaccine was obtained from meta-analyses of the published literature for healthy adults and the elderly [23,41]. For pregnant women [15,25], infants aged 0–5 months [3,15,25], and children aged 6–23 months [22,42] we performed random effects meta-analyses of published randomized controlled trials (RCTs) of influenza VE (see results in Supplemental Information). There were no estimates of influenza VE in persons with tuberculosis disease and there are few RCTs that evaluate VE against laboratory-confirmed influenza infection in persons with chronic illnesses as most have looked at a single disease and at alternative endpoints (exacerbations, etc.). For this reason, we used the VE estimate for adults aged 65 years and older to score these two risk groups (Table 2). We assumed VE against influenza-associated hospitalization or death was equal to VE against laboratory-confirmed influenza-associated illness.

Table 2.

Summary of population size, influenza-associated hospitalization rates, influenza-associated death rates, vaccine efficacy, potential hospitalizations averted per 100,000 vaccinated, potential deaths averted per 100,000 vaccinated, and vaccine coverage by high risk group, South Africa.

Risk group Mid-year population in South Africa (2016) Age and HIV-standardized rate of influenza-associated hospitalization per 100,000 person years (95% CI) Age and HIV-standardized rate of influenza-associated death per 100,000 person years (95% CI) Vaccine efficacy* in risk group Potential hospitalizations averted per 100,000 vaccinated (95% CI) Potential deaths averted per 100,000 vaccinated (95% CI) Vaccine coverage**
Pregnant women 1,198,861 (births)

270,235 HIV-infected (22.5%)		 378.8 (237.7–534.8) 12.6 (7.2–18.0) 61% (95% CI, 43–73%) n = 6430 228.5 (130.8–362.4)

27.8 (15.3–40.6)*** 		7. 7(3.9–12.0)

7.8 (5.1–10.7)*** 		14%

Tetanus toxoid 2 dose coverage 80% in 2015
HIV-infected adults aged 15–64 years 6,604,709 256.3 (179.4–333.2) 64.7 (38.3–81.1) 76% (95% CI, 9–96%), n = 506 190.9 (24.5–390.6) 48.2 (6.1–102.3) 3%
Children aged 6–23 months 1,729,502

15,911 HIV-infected (0.9%)		 324.1 (237.6 – 417.8) 23.4 (5.1 – 26.5) 35% (95% CI, −41–70%), n = 1893 111.6 (1.1 – 238.3) 8.0 (0.1–18.3) 3%

Measles vaccine 2 dose coverage 63% in 2015
Adults aged ≥ 65 years 2,909,122

97,640 HIV-infected (3.36%)		 194 (144–256) 169.3 (81.0–324.6) 58% (95% CI, 40–70%), n = 11,848 111.0 (70.3 – 160.7) 96.6 (26.2–180.9) 2%
Healthcare workers 566,393

88,924 HIV-infected (15.7%)		 60.6 (45.5 – 75.8) 20.9 (9.4–29.0) 60% (95% CI, 53–66%), n = 51,724 36.1 (26.5–46.3) 12.5 (6.6–18.7) 10%
Adults and children with TB (all ages) 318,193 notified cases in 2014 ( ≥ 60% HIV-infected) 282.7 (193.5–377.4) 164 (144–174) Unknown; used estimate in elderly 58% (95% CI, 40–70%), n = 11,848 162.0 (96.6 – 245.1) 95.0 (64.0 – 127.3) 3%
Adults and children aged 5–64 years with other chronic illnesses 9,863,353 42.4 (31.8 – 53.7) 24.4 (15.4 – 35.3) Unknown; used estimate in elderly 58% (95% CI, 40–70%), n = 11,848 29.4 (15.5 – 44.7) 16.7 (8.3–28.3) 3%
Open in a new tab
*

Against laboratory-confirmed influenza-associated illness.

**

2015 national estimates for all risk groups except healthcare workers.

***

Due to timing of maternal vaccination only 8–10% of burden in infants may be averted (M. Biggerstaff, in preparation).

2.5. Vaccine coverage estimates

Each year the South African National Department of Health produces estimates of influenza vaccine coverage by target group. Target groups with estimated vaccine coverage in 2015 were pregnant women, children age 6–59 months, adults aged ≥65 years and persons with chronic illness (including HIV-infected adults) [43]. We did not find a local estimate of influenza vaccine coverage among healthcare workers so we used an average estimate of 10% from low and middle-income countries from the literature [44].

2.6. Coverage-adjusted hospitalization and mortality scores by risk group

To define target vaccine coverage we modified estimates of vaccine coverage from other vaccines targeting similar risk groups (e.g. tetanus vaccine coverage for pregnant women) [45] assuming an annual campaign of approximately 3 months duration2 would cover 50% of the annual coverage or, for groups with no current immunization platform, 80% of individuals presenting to a clinic in a 3-month period (20% for persons with HIV, TB and other chronic illness, 10% for persons aged ≥65 years). We assumed that healthcare worker vaccination coverage could be increased to 80% with improved access and education [44].

2.7. Estimated rate of hospitalizations/deaths averted by vaccination

We used the following formula to estimate the rate of hospitalizations (or deaths) averted by vaccination in each risk group: rate of influenza-associated hospitalization (or death) per 100,000 population * influenza vaccine efficacy. Monte Carlo simulations using 5000 iterations based on a Poisson distribution in SAS 9.3 (SAS Institute, Cary, NC) were used to develop means and 95% confidence intervals for estimates of the rate of influenza-associated hospitalizations (or deaths) averted per 100,000 vaccinated and an overall population-weighted estimate of the rate of influenza-associated hospitalizations (or deaths) averted per 100,000 vaccinated. The parameters used for the calculations are provided in Table 2.

2.8. Cost per hospital day averted/year of life saved

We also examine the potential years of life saved by vaccinating 100,000 individuals in each target group and the cost per year of life saved. The cost of vaccinating 100,000 individuals was estimated as the single dose vaccine price (~USD3) * 100,000 for all groups except children aged 6–23 months for whom the price was doubled3 [46]. Mean duration of hospitalization was estimated from local severe respiratory illness surveillance data. The cost per hospital day averted was calculated by dividing the cost of vaccinating 100,000 individuals by the product of the mean hospitalization duration and the estimated hospitalizations averted per 100,000 vaccinated. Estimated years of life saved was calculated for each risk group based upon expectation of life in years by age [47] and HIV-status [48]. The cost per year of life saved was calculated by dividing the cost of vaccinating 100,000 individuals by the product of the mean years of life saved per death averted and the estimated deaths averted per 100,000 vaccinated. The estimated hospitalizations and deaths averted by the current program and the target influenza vaccination programs were determined by multiplying the number of doses administered/100,000 by the rate of hospitalizations and deaths averted per 100,000 vaccinated.

3. Results

3.1. Hospitalizations averted per 100,000 vaccinated

Pregnant women had the highest estimated rate of hospitalizations averted per 100,000 vaccinated at 228.5 (95% CI 130.8–362.4) in addition to the benefit conferred to their infants aged 0–5 months (Table 2). Adults with HIV-infection, adults and children with tuberculosis disease, and adults aged 65 years or older also had high rates of hospitalization averted per 100,000 vaccinated at 190.9 (95% CI 24.5–390.6), 162.0 (95% CI 96.6–245.1), and 111.0 (95% CI 70.3–160.7), respectively. Young children aged 6–23 months had high rates of hospitalization averted per 100,000 vaccinated with wide confidence intervals (111.6, 95% CI 1.1–238.3) due to variable vaccine efficacy. Healthcare workers and adults and children aged 5–64 years with chronic illness had lower rates of hospitalization averted per 100,000 vaccinated at 36.1 (95% CI 26.5–46.3) and 29.4 (95% CI 15.5–44.7), respectively.

3.2. Deaths averted per 100,000 vaccinated

In South Africa, the majority of influenza-associated deaths occur in older adults and this resulted in adults aged ≥ 65 years having the highest estimated rate of deaths averted per 100,000 vaccinated, 96.6 (95% CI 26.2–180.9). Adults and children with TB disease also had very high rates of deaths averted per 100,000 vaccinated, 95.0 (95% CI 64.0–127.3). HIV-infected adults also had moderately high rates of deaths averted per 100,000 vaccinated, 18.2 (95% CI 6.1–102.3). Due to lower mortality rates, pregnant women, young children, healthcare workers and those with non-HIV chronic illness had lower estimates of deaths averted per 100,000 (Table 2).

3.3. Coverage-adjusted hospitalization and mortality scores by risk group

Many LMIC, including South Africa, provide immunization services to young children and pregnant women but few may offer immunization services to other risk groups. Therefore, countries introducing influenza vaccination programs may have to assess the opportunity costs associated with vaccinating persons outside these existing programs. We adjusted hospitalization and mortality rates per 100,000 by current and proposed target vaccine coverage to include an assessment of feasibility in our discussion of prioritization. Based upon coverage-adjusted hospitalization and mortality scores pregnant women remain the highest priority for averting hospitalizations (target score 102.5); adults and children with TB disease and healthcare workers increase in relative prioritization based upon target mortality scores (scores 19.0 and 10.0, respectively) (Table 3). HIV-infected adults remain an important risk group in both coverage-adjusted hospitalization and mortality scores, and the elderly remain an important risk group based upon mortality scores.

Table 3.

Summary of 2016 vaccine coverage, target vaccine coverage and coverage-adjusted hospitalization and mortality scores by high risk group, South Africa.

Risk group 2015 vaccine coverage** Current coverage-adjusted hospitalization score Current coverage-adjusted mortality score Target vaccine coverage Target coverage-adjusted hospitalization score Target coverage-adjusted mortality score
Pregnant women 14% 35.8 (20.5–56.4) 2.2 (1.3–3.2) 40% 102.5 (58.4–161.2) 6.2 (3.6–9.1)
HIV-infected adults aged 15–64 years 3% 5.7 (0.7–11.7) 1.4 (0.2–3.1) 20% 38.2 (4.9–78.1) 9.6 (1.2–20.5)
Children aged 6–23 months 3% 3.3 (0.0–7.1) 0.2 (0.0–0.5) 32% 35.6 (0.4–76.3) 2.9 (0.0–5.9)
Adults aged ≥ 65 years 2% 2.2 (1.4–3.2) 1.9 (0.5–3.6) 10% 11.1 (7.0–16.1) 9.7 (2.6–18.1)
Healthcare workers 10% 3.6 (2.6–4.6) 1.3 (0.7–1.9) 80% 28.8 (21.2–37.0) 10.0 (5.3–15.0)
Adults and children with TB (all ages) 3% 4.9 (2.9–7.4) 2.9 (1.9–3.8) 20% 32.4 (19.3–49.0) 19.0 (12.8–25.5)
Adults and children aged 5–64 years with other chronic illnesses 3% 0.9 (0.5–1.3) 0.5 (0.2–0.8) 20% 5.9 (3.1–8.9) 3.3 (1.7–5.7)
Open in a new tab
**

2015 national estimates for all risk groups except healthcare workers.

3.4. Cost per hospital day averted and cost per year of life saved

The cost per hospital day averted ranged from USD148–1,344 with a population-weighted mean of USD386 (95% CI 244–761) (Table 4). Cost per hospital day averted was lowest among pregnant women and their infants (USD148), HIV-infected adults (USD196), and adults and children with TB (USD206). The highest costs per hospital day averted were in children aged 6–23 months (USD1,344) and adults and children aged 5–64 years with non-HIV, non-TB chronic illnesses (USD1,276). The cost per year of life saved ranged from USD112–1,230 with a population weighted mean of USD429 (95% CI 226–1,425) and was lowest among adults and children with TB (USD112), HIV-infected adults (USD257), and pregnant women (USD373) (Table 4).

Table 4.

Estimated cost per hospital day averted and cost per year of life saved by influenza vaccination in selected risk groups, South Africa, 2016.

Risk group Mean duration of hospitalization in days (standard deviation) Cost per hospital day averted (USD) (95% CI) Average years of life lost per death Average years of life saved per 100,000 vaccinated (95% CI) Cost per year of life saved (USD) (95% CI)
Pregnant women -and- Infants aged 0–5 months 7 (9)
9 (9)		 148 (103–285) 43 60 805 (477–1166) 373 (257–629)
HIV-infected adults aged 15–64 years 8 (9) 196 (96–1,531) 24 1166 (148–2476) 257 (121–2,032)
Children aged 6–23 months 4 (6) 1,344 (629–136,364) 61 488 (6–1116) 1230 (537–98,361)
Adults aged ≥ 65 years 8 (9) 338 (233–533) 7 628 (170–1176) 478 (255–1,762)
Healthcare workers 8 (8) 1,039 (810–1,415) 30 370 (195–554) 811 (542–1,536)
Adults and children with TB 9 (10) 206 (136–345) 28 2689 (1811–3603) 112 (83–166)
Adults and children aged 5–64 years with other chronic diseases 8 (9) 1,276 (839–2,419) 31 511 (254–866) 587 (346–1,181)
Total 8 (9) 386 (244–761) 32 752 (226–1427) 429 (226–1,425)
Open in a new tab

3.5. Estimated current and target vaccine coverage and impact

The estimated number of South Africans that fall into one or more risk categories was over 23 million in 2016. Current vaccination coverage in the public sector is less than 5% in all risk groups except pregnant women (14%). Despite relatively low coverage, our simple model estimated 1054 (95% CI 405–1,849) hospitalizations and 247 (95% CI 99–431) deaths might have been averted in 2016. At approximately USD3 per dose of influenza vaccine, the cost per hospitalization averted was approximately USD2,386 (95% CI 1,360–6,203) and the cost per death averted was USD10,200 (95% CI 5,836–25,426). If resources allocated to influenza vaccine procurement were increased, the proposed target program could potentially avert 5,538 (95% CI 1,722–10,126) hospitalizations and 1,478 (95% CI 545–2,656) deaths (Table 5). At the same cost per dose, the cost per hospitalization averted would be approximately USD2,781 (95% CI 1,521–8,943) and the cost per death averted would be USD10,420 (95% CI 5,800–28,270).

Table 5.

Estimated hospitalizations and deaths potentially averted in current and target influenza vaccination programs, South Africa, 2016.

Risk group Number vaccinated by current program (% target population) Estimated hospitalizations averted by current program (95% CI) Estimated deaths averted by current program (95% CI) Number vaccinated with target coverage* (% target population) Estimated hospitalizations averted by target program (95% CI) Estimated deaths averted by target program (95% CI)
Pregnant women -and- Infants aged 0–5 months 167,840 (14) 430 (245–676) 26 (15–38) 479,544 (40) 1229 (701–1933) 74 (43–109)
HIV-infected adults aged 15– 64 years 198,141 (3) 378 (49–774) 96 (12–203) 1,320,942(20) 2522 (324–5160) 637 (81–1351)
Children aged 6–23 months 51,885 (3) 58 (1–124) 4 (0–9) 553,441 (32) 618 (6–1319) 44 (1–101)
Adults aged ≥ 65 years 58,182 (2) 65 (41–93) 55 (37–74) 290,912 (10) 323 (205–467) 276 (186–370)
Healthcare workers 56,639 (10) 20 (15–26) 7 (4–11) 453,114 (80) 164 (120–210) 57 (30–85)
Adults and children with TB 9,546 (3) 15 (9–23) 9 (6–12) 63,639 (20) 103 (61–156) 60 (41–81)
Adults and children with other chronic illnesses 295,901 (3) 87 (46–132) 49 (25–84) 1,972,671 (20) 580 (306–882) 329 (164–558)
Total 838,134 (4) 1054 (405–1849) 247 (99–431) 5,134,263 (22) 5,538 (1,722–10,126) 1,478 (545–2,656)
Open in a new tab
*

Target vaccine coverage derived from 50% coverage with an existing vaccination platform or assumption of 80% coverage of individuals presenting over a 3-month vaccination period.

4. Discussion

Hospitalization rates and mortality rates due to influenza-associated illness may differ in LMIC, there are cultural differences in care-seeking for severe respiratory illness, and there are few public sector programs that routinely provide immunization and preventive care services. Considering all of these factors in prioritization of risk groups for influenza vaccine introduction is essential to program acceptance and success in resource-limited settings. Prior studies of influenza vaccine prioritization have focused on minimizing years of life lost [49], on individuals at high-risk of complications [50] or on reducing transmission by vaccinating children [51] during pandemics. This analysis is a first attempt at applying similar concepts to routine annual influenza vaccination.

In South Africa, adults and children with TB, HIV-infected adults, and pregnant women had among the lowest costs per hospital day averted and year of life saved. While the elderly rank highest when considering potential deaths averted per 100,000 vaccinated, their lower hospitalization rates and lower years of life lost per death increased the cost per hospital day averted and per year of life saved. Lower vaccine efficacy and the need for 2 doses of influenza vaccine in children aged 6–23 months who have not been previously vaccinated increase the cost per hospital day averted and per year of life saved for this risk group.

There are several limitations to this methodology. First, data on vaccine efficacy in some risk groups were extremely limited. There were no data on influenza vaccine efficacy in persons with tuberculosis disease. Vaccine efficacy data in children aged 6–23 months and HIV-infected adults were also limited. Second, we assumed influenza vaccine efficacy would be the same for influenza-associated hospitalization or death as it is against laboratory-confirmed influenza-associated illness, where most data are collected among outpatients. Third, our estimates of cost per hospital day averted or year of life saved do not include adjustments for vaccine delivery or administration. It was challenging to separate administration costs because there were no additional staff hired to administer immunizations during annual influenza vaccination campaigns. Fortunately, administration and transportation costs should be similar across risk groups and would therefore be less likely to affect relative prioritization. Fourth, we only assessed the potential impact of trivalent inactivated influenza vaccines. Newer vaccines that may differentially increase vaccine efficacy in risk groups might impact the relative prioritization of risk groups. Finally, the results are based on prevention of influenza-associated hospitalization or death and do not assess potential impact of vaccination on disease transmission or productivity loss. Including indirect effects of vaccination on influenza transmission might improve overall estimates of cost effectiveness or result in different prioritization of risk groups.

Prior modelling of the impact of influenza vaccination on disease burden in pregnant women and infants was able to inform estimates of the fraction of infant disease potentially averted through maternal vaccination [52] (M Biggerstaff, personal communication). For other risk groups we assumed that vaccine effectiveness was equivalent to published estimates of efficacy. This assumption may be incorrect in that not all persons may have received vaccination prior to the onset of the influenza season, vaccine effectiveness varies depending on how well the vaccine strains match the circulating strains, and vaccine effectiveness may wane during the season.

South Africa has published rates of influenza-associated illness and death in most of the vaccine target groups. Likewise, population estimates from census data, disease modelling, or other sources were available for most risk groups. However, there were few published estimates of the prevalence of common co-morbid conditions in South Africa and none that assessed the prevalence of any co-morbid condition (i.e. one or more conditions). By using the SA NHANES survey data we estimated the prevalence of any common chronic illness; however, the SA NHANES did not document all underlying illnesses nor the HIV status of participants. We attempted to adjust for the increased prevalence of comorbid conditions among HIV-infected children and adults in estimating the prevalence of other chronic illnesses in HIV-uninfected children and adults but there were no data available on such adjustments in a LMIC setting.

Finally, we did not include formal cost-effectiveness analyses for each risk group. We have recently collected costing data for respiratory illnesses in South Africa and hope to produce estimates of influenza vaccine cost effectiveness in the future.

5. Conclusions

In 2016, the National Advisory Group on Immunization in South Africa recommended that pregnant women and HIV-infected persons be prioritized for publicly funded influenza vaccination given available evidence on influenza-associated disease burden and a preliminary version of this analysis (S. Walaza, personal communication). These two risk groups had the highest rates of potential hospitalizations averted and were among the lowest cost per hospital day averted and year of life saved. Only adults and children with TB disease had lower cost per hospital day averted and year of life saved but this group was not prioritized given the lack of available data on influenza vaccine efficacy.

Supplementary Material

2

Acknowledgements

The authors would like to gratefully acknowledge the contributions of the following persons: Professor Demetre Labadarios and team at the Human Sciences Research Council for access to SA NHANES data, the Communicable Disease Cluster of the National Department of Health in South Africa for access to influenza vaccine coverage data, and the surveillance officers, laboratorians, and participants that support the national pneumonia surveillance program in South Africa.

Funding source

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Footnotes

Conflicts of interest

Dr. Shabir Madhi has received grants from the US Centers for Disease Control and Prevention, the Bill and Melinda Gates Foundation, Pfizer, GlaxoSmithKline and Novartis, and personal fees from the Bill and Melinda Gates Foundation. Dr. Cheryl Cohen has received grants from the US Centers for Disease Control and Prevention and Sanofi Pasteur and travel expenses paid by Parexel. The remaining authors have no conflict of interest to report.

Disclaimer

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

1

In this analysis, we included children aged 6–23 months rather than children aged 6–59 months because few children aged 24–59 months are routinely seen in vaccination clinics in South Africa.

2

Unpublished data from the South African Department of Health demonstrate that during 2015–2017 75–96% of influenza vaccines administered were delivered within 3 months, typically April-June.

3

Cost was doubled for children aged 6–23 months because they require 2 doses of influenza vaccine.

Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.vaccine.2018.11.048.

References

  • [1].Meeting of the Strategic Advisory Group of Experts on Immunization, November 2011 - conclusions and recommendations. Weekly epidemiological record/Health Section of the Secretariat of the League of Nations. 2012:1–16. [Google Scholar]
  • [2].Meeting of the Strategic Advisory Group of Experts on immunization, April 2015: conclusions and recommendations. Weekly epidemiological record /Health Section of the Secretariat of the League of Nations. 2015;90(22):261–78. [PubMed] [Google Scholar]
  • [3].Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008;359(15):1555–64. [DOI] [PubMed] [Google Scholar]
  • [4].Steinhoff MC, Omer SB, Roy E, El Arifeen S, Raqib R, Dodd C, et al. Neonatal outcomes after influenza immunization during pregnancy: a randomized controlled trial. CMAJ 2012;184(6):645–53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [5].Black SB, Shinefield HR, France EK, Fireman BH, Platt ST, Shay D, et al. Effectiveness of influenza vaccine during pregnancy in preventing hospitalizations and outpatient visits for respiratory illness in pregnant women and their infants. Am J Perinatol 2004;21(6):333–9. [DOI] [PubMed] [Google Scholar]
  • [6].Moro PL, Broder K, Zheteyeva Y, Walton K, Rohan P, Sutherland A, et al. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990–2009. Am J Obstetrics Gynecol 2011;204(2). 146e1–e7. [DOI] [PubMed] [Google Scholar]
  • [7].Tamma PD, Ault KA, del Rio C, Steinhoff MC, Halsey NA, Omer SB. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol 2009;201 (6):547–52. [DOI] [PubMed] [Google Scholar]
  • [8].Radin JM, Katz MA, Tempia S, Nzussouo NT, Davis R, Duque J, et al. Influenza surveillance in 15 countries in Africa, 2006–2010. J Infect Dis 2012;206(Suppl 1):S14–21. [DOI] [PubMed] [Google Scholar]
  • [9].Savy V, Ciapponi A, Bardach A, Glujovsky D, Aruj P, Mazzoni A, et al. Burden of influenza in Latin America and the Caribbean: a systematic review and meta-analysis. Influenza Other Respir Viruses 2013;7(6):1017–32. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [10].Fischer WA 2nd, Gosng M, Bhagwanjee S, Sevransky J. Global burden of influenza as a cause of cardiopulmonary morbidity and mortality. Glob Heart 2014;9(3):325–36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [11].Van Kerkhove MD, Vandemaele KA, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly CA, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med. 2011;8 (7):e1001053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12].Lafond KE, Nair H, Rasooly MH, Valente F, Booy R, Rahman M, et al. Global role and burden of influenza in pediatric respiratory hospitalizations, 1982–2012: A systematic analysis. PLoS Med 2016;13(3):e1001977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [13].Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2011;378(9807):1917–30. [DOI] [PubMed] [Google Scholar]
  • [14].Pretorius MA, Madhi SA, Cohen C, Naidoo D, Groome M, Moyes J, et al. Respiratory viral coinfections identified by a 10-plex real-time reverse-transcription polymerase chain reaction assay in patients hospitalized with severe acute respiratory illness–South Africa, 2009–2010. J Infect Dis 2012;206 (Suppl 1):S159–65. [DOI] [PubMed] [Google Scholar]
  • [15].Tempia S, Walaza S, Viboud C, Cohen AL, Madhi SA, Venter M, et al. Mortality associated with seasonal and pandemic influenza and respiratory syncytial virus among children <5 years of age in a high HIV prevalence setting–South Africa, 1998–2009. Clin Infect Dis 2014;58(9):1241–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [16].Tempia S, Walaza S, Viboud C, Cohen AL, Madhi SA, Venter M, et al. Deaths associated with respiratory syncytial and influenza viruses among persons >/=5 years of age in HIV-prevalent area, South Africa, 1998–2009(1). Emerg Infect Dis 2015;21(4):600–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [17].Cohen C, Moyes J, Tempia S, Groom M, Walaza S, Pretorius M, et al. Severe influenza-associated respiratory infection in high HIV prevalence setting, South Africa, 2009–2011. Emerg Infect Dis 2013;19(11):1766–74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [18].Cohen C, Moyes J, Tempia S, Groome M, Walaza S, Pretorius M, et al. Mortality amongst patients with influenza-associated severe acute respiratory illness, South Africa, 2009–2013. PLoS ONE 2015;10(3):e0118884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [19].Walaza S, Cohen C, Nanoo A, Cohen AL, McAnerney J, von Mollendorf C, et al. Excess mortality associated with influenza among tuberculosis deaths in South Africa, 1999–2009. PLoS ONE 2015;10(6):e0129173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [20].Tempia S, Wolter N, Cohen C, Walaza S, von Mollendorf C, Cohen AL, et al. Assessing the impact of pneumococcal conjugate vaccines on invasive pneumococcal disease using polymerase chain reaction-based surveillance: an experience from South Africa. BMC Infect Dis 2015;15:450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [21].Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V, Ferroni E. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2012;8: CD004879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [22].Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011;365(15):1406–16. [DOI] [PubMed] [Google Scholar]
  • [23].Darvishian M, Bijlsma MJ, Hak E, van den Heuvel ER. Effectiveness of seasonal influenza vaccine in community-dwelling elderly people: a meta-analysis of test-negative design case-control studies. Lancet Infect Dis 2014;14 (12):1228–39. [DOI] [PubMed] [Google Scholar]
  • [24].McGrath LJ, Kshirsagar AV, Cole SR, Wang L, Weber DJ, Sturmer T, et al. Influenza vaccine effectiveness in patients on hemodialysis: an analysis of a natural experiment. Arch Intern Med 2012;172(7):548–54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [25].Tapia MD, Sow SO, Tamboura B, Teguete I, Pasetti MF, Kodio M, et al. Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial. Lancet Infect Dis 2016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [26].Cohen C, Simonsen L, Sample J, Kang JW, Miller M, Madhi SA, et al. Influenza-related mortality among adults aged 25–54 years with AIDS in South Africa and the United States of America. Clin Infect Dis 2012;55(7):996–1003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [27].Tempia S, Walaza S, Moyes J, Cohen AL, von Mollendorf C, Treurnicht FK, et al. Risk factors for influenza-associated severe acute respiratory illness hospitalization in South Africa, 2012–2015. Open Forum. Infect Dis 2017;4 (1):ofw262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [28].Case AMA, and Ardington C. Health Seeking Behavior in Northern KwaZulu-Natal: Princeton University; 2005. [Google Scholar]
  • [29].Ott JJ, Klein Breteler J, Tam JS, Hutubessy RC, Jit M, de Boer MR. Influenza vaccines in low and middle income countries: a systematic review of economic evaluations. Hum Vaccin Immunother 2013;9(7):1500–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [30].Fell DB, Savitz DA, Kramer MS, Gessner BD, Katz MA, Knight M, et al. Maternal influenza and birth outcomes: systematic review of comparative studies. BJOG 2017;124(1):48–59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [31].Statistical release P0302: Mid-year population estimates, 2016. Pretoria, South Africa: 2016. [Google Scholar]
  • [32].Johnson LF, Chiu C, Myer L, Davies MA, Dorrington RE, Bekker LG, et al. Prospects for HIV control in South Africa: a model-based analysis. Glob Health Action 2016;9:30314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [33].Shisana OLD, Rehle T, & the SANHANES-1 Team. South African National Health and Nutrition Examination Survey (SANHANES-1): 2014 Edition. Cape Town: HSRC Press; 2014. [Google Scholar]
  • [34].Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis 2014;59(12):1787–97. [DOI] [PubMed] [Google Scholar]
  • [35].Tempia S, Walaza S, Moyes J, Cohen AL, von Mollendorf C, McMorrow ML, et al. The effects of the attributable fraction and the duration of symptoms on burden estimates of influenza-associated respiratory illnesses in a high HIV-prevalence setting, South Africa, 2013–2015. Influenza Other Respir Viruses 2017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [36].McMorrow ML, Tempia S, Walaza S, Treurnicht FK, Moyes J, Cohen AL, et al. The role of HIV in influenza- and respiratory syncytial virus-associated hospitalizations in South African children, 2011–2016. Clin Infect Dis 2018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [37].Abadom TR, Smith AD, Tempia S, Madhi SA, Cohen C, Cohen AL. Risk factors associated with hospitalisation for influenza-associated severe acute respiratory illness in South Africa: a case-population study. Vaccine 2016;34 (46):5649–55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [38].Mertz D, Kim TH, Johnstone J, Lam PP, Science M, Kuster SP, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ 2013;347:f5061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [39].Tempia S, Walaza S, Cohen AL, von Mollendorf C, Moyes J, McAnerney JM, et al. Mortality associated with seasonal and pandemic influenza among pregnant and nonpregnant women of childbearing age in a high-hiv-prevalence setting-South Africa, 1999–2009. Clin Infect Dis 2015;61(7):1063–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [40].Cohen C, Walaza S, Treurnicht FK, McMorrow M, Madhi SA, McAnerney JM, et al. In- and out-of-hospital mortality associated with seasonal and pandemic influenza and respiratory syncytial virus in South Africa, 2009–2013. Clin Infect Dis 2017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [41].Vaccines for preventing influenza in healthy adults [Internet]. 2014. [cited November 21, 2016]. Available from: www.cochranelibrary.com.
  • [42].Hoberman A, Greenberg DP, Paradise JL, Rockette HE, Lave JR, Kearney DH, et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA 2003;290 (12):1608–16. [DOI] [PubMed] [Google Scholar]
  • [43].Ramkrishna W Trends in influenza vaccine coverage of high risk groups in South Africa (2011–2015), prior to influenza policy implementation. Options IX for the Control of Influenza; August 27, 2016; Chicago, Illinois: International Society for Influenza and other Respiratory Virus Diseases (ISIRV); 2016. [Google Scholar]
  • [44].Haviari S, Benet T, Saadatian-Elahi M, Andre P, Loulergue P, Vanhems P. Vaccination of healthcare workers: a review. Hum Vaccin Immunother 2015;11(11):2522–37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [45].Horton KC, Dueger EL, Kandeel A, Abdallat M, El-Kholy A, Al-Awaidy S, et al. Viral etiology, seasonality and severity of hospitalized patients with severe acute respiratory infections in the Eastern Mediterranean Region, 2007–2014. PLoS ONE 2017;12(7):e0180954. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [46].Pan American Health Organization. Expanded Program of Immunization Vaccine Prices for Year 2016. 2016 [Available from: http://www2.paho.org/hq/index.php?option=com_content&view=article&id=6207%3A2011-about-influenza-vaccine&catid=4204%3Ainfluenza-vaccine&Itemid=4322&lang=en
  • [47].World Health Organization. Global Health Observatory 2015. [Available from: https://knoema.com/WHOGHO2015/global-health-observatory-2015?location=1001850-south-africa&indicator=1007590-ex-expectation-of-life-at-age-x [Google Scholar]
  • [48].Johnson LF, Mossong J, Dorrington RE, Schomaker M, Hoffmann CJ, Keiser O, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med 2013;10(4):e1001418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [49].Miller MA, Viboud C, Olson DR, Grais RF, Rabaa MA, Simonsen L. Prioritization of influenza pandemic vaccination to minimize years of life lost. J Infect Dis 2008;198(3):305–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [50].Mylius SD, Hagenaars TJ, Lugner AK, Wallinga J. Optimal allocation of pandemic influenza vaccine depends on age, risk and timing. Vaccine 2008;26(29–30):3742–9. [DOI] [PubMed] [Google Scholar]
  • [51].Lee BY, Brown ST, Korch GW, Cooley PC, Zimmerman RK, Wheaton WD, et al. A computer simulation of vaccine prioritization, allocation, and rationing during the 2009 H1N1 influenza pandemic. Vaccine 2010;28(31):4875–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [52].McMorrow ML, Emukule GO, Obor D, Nyawanda B, Otieno NA, Makokha C, et al. Maternal influenza vaccine strategies in Kenya: which approach would have the greatest impact on disease burden in pregnant women and young infants? PLoS ONE 2017;12(12):e0189623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [53].Health Professions Council of South Africa. Summary of Registered Persons 2016. [updated May 3, 2016 Available from: http://www.hpcsa.co.za/Publications/Statistics
  • [54].South Africa Nursing Council. Registrations and Listed Qualifications Calendar Year 2015 2015. [Available from: http://www.sanc.co.za/stats/Stat2015/Year%202015%20Registrations%20of%20Practitioners%20Stats.pdf
  • [55].Shisana O, Hall EJ, Maluleke R, Chauveau J, Schwabe C. HIV/AIDS prevalence among South African health workers. S Afr Med J 2004;94(10):846–50. [PubMed] [Google Scholar]
  • [56].Tuberculosis country profiles: South Africa: World Health Organization; 2015. [Available from: http://www.who.int/tb/country/data/profiles/en/
  • [57].Lawn SD, Bekker LG, Middelkoop K, Myer L, Wood R. Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis 2006;42(7):1040–7. [DOI] [PubMed] [Google Scholar]
  • [58].Madhi SA, Maskew M, Koen A, Kuwanda L, Besselaar TG, Naidoo D, et al. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis 2011;52(1):128–37. [DOI] [PubMed] [Google Scholar]
  • [59].Michiels B, Govaerts F, Remmen R, Vermeire E, Coenen S. A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine. 2011;29(49):9159–70. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

2
NIHMS1012564-supplement-2.docx (32.5KB, docx)

RESOURCES